Short Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Expands By 71.6%

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the recipient of a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 9,710,000 shares, an increase of 71.6% from the April 30th total of 5,660,000 shares. Approximately 8.1% of the shares of the company are sold short. Based on an average daily volume of 770,900 shares, the short-interest ratio is presently 12.6 days.Get Lyell Immunopharma alerts:Analyst Ratings ChangesSeparately, HC Wainwright reissued a "neutral" rating and set a $1.00 price target on shares of Lyell Immunopharma in a report on Wednesday, April 16th.Check Out Our Latest Report on Lyell ImmunopharmaLyell Immunopharma Trading Up 1.9%LYEL traded up $0.01 on Friday, reaching $0.41. The company had a trading volume of 865,368 shares, compared to its average volume of 1,034,945. The company has a fifty day moving average of $0.44 and a 200-day moving average of $0.61. The company has a market capitalization of $120.88 million, a P/E ratio of -0.52 and a beta of -0.25. Lyell Immunopharma has a one year low of $0.39 and a one year high of $2.80. Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The firm had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. Research analysts predict that Lyell Immunopharma will post -0.78 EPS for the current year. Insider Buying and Selling at Lyell ImmunopharmaIn other news, CEO Lynn Seely purchased 175,000 shares of Lyell Immunopharma stock in a transaction dated Friday, March 14th. The stock was bought at an average price of $0.61 per share, with a total value of $106,750.00. Following the completion of the acquisition, the chief executive officer now owns 712,500 shares in the company, valued at $434,625. The trade was a 32.56% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sumant Ramachandra purchased 200,000 shares of Lyell Immunopharma stock in a transaction dated Friday, March 21st. The shares were purchased at an average cost of $0.58 per share, with a total value of $116,000.00. Following the acquisition, the director now owns 200,000 shares of the company's stock, valued at approximately $116,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 768,640 shares of company stock worth $449,508 over the last 90 days. Insiders own 25.10% of the company's stock. Hedge Funds Weigh In On Lyell ImmunopharmaInstitutional investors and hedge funds have recently bought and sold shares of the stock. Graham Capital Management L.P. bought a new position in Lyell Immunopharma in the 4th quarter valued at about $33,000. RPO LLC acquired a new stake in Lyell Immunopharma in the 4th quarter valued at about $42,000. Wells Fargo & Company MN lifted its holdings in Lyell Immunopharma by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock valued at $60,000 after acquiring an additional 20,542 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Lyell Immunopharma in the 4th quarter valued at about $64,000. Finally, SG Americas Securities LLC lifted its holdings in Lyell Immunopharma by 102.8% in the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock valued at $75,000 after acquiring an additional 59,182 shares during the last quarter. Institutional investors own 66.05% of the company's stock. Lyell Immunopharma Company Profile (Get Free Report)Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.See AlsoFive stocks we like better than Lyell ImmunopharmaThe 3 Best Fintech Stocks to Buy NowNear 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a LookWhat Are the FAANG Stocks and Are They Good Investments?3 Overlooked Dividend Plays for Income in Volatile TimesHow to Short a Stock in 5 Easy Steps AXON: Competition Intensifies as Motorola Makes $4.4B AcquisitionThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Lyell Immunopharma Right Now?Before you consider Lyell Immunopharma, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here